# Amphastar Pharmaceuticals, Inc. - Inspection Records

Source: https://www.keypedia.com/companies/amphastar-pharmaceuticals-inc/e90eb882-5679-4c85-bbc8-f69ca69cc537

> Inspection records and compliance data for Amphastar Pharmaceuticals, Inc. in Rancho Cucamonga, California. Access full analysis and detailed observations.

---

## Details

- Name: Amphastar Pharmaceuticals, Inc.
- FEI Number: 3002936358
- City: Rancho Cucamonga
- State: California
- Country Name: United States
- Address Line 1: 11570 6th St
- Zip Code: 91730
- Business Operations: API/FDF ANALYTICAL TESTING, CLINICAL BIOEQUIVALENCE OR BIOAVAILABILITY STUDY, FDF MANUFACTURE, IN VITRO BIOEQUIVALENCE OR BIOANALYTICAL TESTING

## Related Documents

- [CRL - Amphastar Pharmaceuticals, Inc. - Unknown Date](https://www.keypedia.com/records/crl/amphastar-pharmaceuticals-inc/1acdb785-a6cd-4a73-acc7-230e9092fbf3) — source: FDA, date: Invalid Date
- [CRL - Amphastar Pharmaceuticals, Inc. - Unknown Date](https://www.keypedia.com/records/crl/amphastar-pharmaceuticals-inc/25af10c9-8faf-4ca2-9e1b-9aba59be2196) — source: FDA, date: Invalid Date
- [483 - Amphastar Pharmaceuticals, Inc. - 2025-11-07](https://www.keypedia.com/records/483/amphastar-pharmaceuticals-inc/9fca3bac-d02d-4ef5-b7cc-ab5e97be5cb7) — source: FDA, date: November 7, 2025
- [FDA Inspection 1290538 - Amphastar Pharmaceuticals, Inc. - 2025-11-07](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/84de8825-ab9e-4fa3-a9c3-56d089df0daa) — source: FDA, date: November 7, 2025
- [FDA Inspection 1266798 - Amphastar Pharmaceuticals, Inc. - 2025-04-03](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/8fb295ef-49db-4a02-b73e-0db8de8dfa2a) — source: FDA, date: April 3, 2025
- [FDA Inspection 1266798 - Amphastar Pharmaceuticals, Inc. - 2025-04-03](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/f3a88961-407c-4d84-af4c-f19faea69e77) — classification: No Action Indicated (NAI), source: FDA, date: April 3, 2025
- [483 - Amphastar Pharmaceuticals, Inc. - 2024-03-01](https://www.keypedia.com/records/483/amphastar-pharmaceuticals-inc/6441e37f-90c5-409d-9e1f-c60acc9218e1) — source: FDA, date: March 1, 2024
- [483 - Amphastar Pharmaceuticals, Inc. - 2024-03-01](https://www.keypedia.com/records/483/amphastar-pharmaceuticals-inc/51a97c4a-18cd-4d34-8ca8-0451323cecd2) — source: FDA, date: March 1, 2024
- [FDA Inspection 1229403 - Amphastar Pharmaceuticals, Inc. - 2024-03-01](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/a2414e67-1cfd-473a-9c8d-0d52c8942976) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 1, 2024
- [FDA Inspection 1144508 - Amphastar Pharmaceuticals, Inc. - 2021-06-22](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/ae9ea154-97df-4795-8830-a2b954052abc) — classification: No Action Indicated (NAI), source: FDA, date: June 22, 2021
- [FDA Inspection 1113865 - Amphastar Pharmaceuticals, Inc. - 2019-11-22](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/0bce91e0-006f-4146-a83a-3eb37a284a7d) — classification: No Action Indicated (NAI), source: FDA, date: November 22, 2019
- [FDA Inspection 1115634 - Amphastar Pharmaceuticals, Inc. - 2019-11-21](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/dacb4d7f-53a1-4f95-a5e0-855a2b408229) — classification: No Action Indicated (NAI), source: FDA, date: November 21, 2019
- [FDA Inspection 1100047 - Amphastar Pharmaceuticals, Inc. - 2019-07-25](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/7765f1b3-8842-4ff0-a466-28d009835711) — classification: No Action Indicated (NAI), source: FDA, date: July 25, 2019
- [FDA Inspection 1009137 - Amphastar Pharmaceuticals, Inc. - 2017-03-31](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/4fa2606f-8c75-403e-bbc7-2e8c7fcf90ac) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 31, 2017
- [FDA Inspection 1009137 - Amphastar Pharmaceuticals, Inc. - 2017-03-31](https://www.keypedia.com/records/fda_inspections/amphastar-pharmaceuticals-inc/197f0b72-c7e5-4db2-9ce9-905c1852636e) — classification: Official Action Indicated (OAI), source: FDA, date: March 31, 2017

## Related Companies

- [Chattem Inc](https://www.keypedia.com/companies/chattem-inc/4ca90cd8-88ca-4db8-ad0b-98e339ee0c0a)
- [International Medication Systems Ltd.](https://www.keypedia.com/companies/international-medication-systems-ltd/d323d576-1c13-498f-af78-08d7cc187625)
- [AbbVie Inc.](https://www.keypedia.com/companies/abbvie-inc/e9d2de86-ad64-4278-8fb3-a8cd7909719e)
- [Thymoorgan Pharmazie Gmbh](https://www.keypedia.com/companies/thymoorgan-pharmazie-gmbh/b58b84eb-57d4-4730-8fbb-58632f71023d)
- [Corden Pharma S.p.A.](https://www.keypedia.com/companies/corden-pharma-spa/9ebac113-b666-42f4-bce9-0183154975f3)
- [OrBion Pharmaceuticals Private Limited](https://www.keypedia.com/companies/orbion-pharmaceuticals-private-limited/1cdc049d-587c-4283-8d5c-8604cff032c9)
- [Ophtapharm AG](https://www.keypedia.com/companies/ophtapharm-ag/bf7065a3-51c2-4dd4-bcac-c2e0ab295ec4)
- [Sunrise Pharmaceutical, Inc.](https://www.keypedia.com/companies/sunrise-pharmaceutical-inc/3e90c0a2-44c0-46f7-a6ff-ee1377824088)
- [Macleods Pharmaceuticals Limited](https://www.keypedia.com/companies/macleods-pharmaceuticals-limited/784654e5-6e07-47f7-9806-dd8c32db2e1d)
- [Lexenpharm (Suzhou) Limited](https://www.keypedia.com/companies/lexenpharm-suzhou-limited/7583aa85-4a9c-4db2-ad49-6d411885ad5f)

## Related Officers

- [Gisela Sharp](https://www.keypedia.com/people/gisela-sharp/bff97a47-05ca-41a4-b9ce-477876596db5)
- [Homero W. Aguilar](https://www.keypedia.com/people/homero-w-aguilar/fbc95655-a1a8-456f-a09a-7bc8a213a786)
- [Chemist/Investigator - Pharmaceutical Quality](https://www.keypedia.com/people/walden-h-lee/18131eea-d1cb-47c4-af79-bea22d436031)
- [Crystal Monroy](https://www.keypedia.com/people/crystal-monroy/b0414886-fb71-4f35-a453-0ad2baf13bfc)